Meeting report: Second Singapore Biologics Manufacturing Conference

Biotechnology Journal

Volumn 2, Issue 6, 2007, Pages 657-658

  Wong, Niki S C ^a   Kocher, Hans P ^b   Yap, Miranda G S ^a  

^a AGENCY FOR SCIENCE   (Singapore)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HAPTEN; INFLUENZA VACCINE; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; WART VIRUS VACCINE; BIOLOGICAL PRODUCT; VACCINE;

BIOTECHNOLOGY; CELL CULTURE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG DESIGN; DRUG MANUFACTURE; DRUG PURIFICATION; FLUORESCENCE ACTIVATED CELL SORTING; PRIORITY JOURNAL; SINGAPORE; VACCINE PRODUCTION; DRUG INDUSTRY; PHARMACEUTICS;

BIOLOGICAL PRODUCTS; DRUG INDUSTRY; SINGAPORE; TECHNOLOGY, PHARMACEUTICAL; VACCINES;

EID: 34447336944     PISSN: 18606768     EISSN: None     Source Type: Journal    
DOI: 10.1002/biot.200790063     Document Type: Conference Paper

References (8)

1. La Merie Business Intelligence Report (2007)
2. Pavlou, A. K., Belsey, M. J., The therapeutic antibodies market to 2008. Eur. J. Pharm. Biopharm. 2005, 59, 389-396.
3. Sheridan, C., The business of making vaccines. Nat. Biotechnol. 2005, 23, 1359-1366.
4. Silverman, J., Liu, Q., Bakker, A., To, W. et al., Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat. Biotechnol. 2006, 23, 1556-61. DOI: 10.1038/ nbt1166.
5. Mazor, Y., Blarcom, T. V., Mabry, R., Iverson, B. L. et al., Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli. Nat. Biotechnol. 2007, 25, 563-565.
6. Wack, A., Rappuoli, R., Vaccinology at the beginning of the 21st century. Curr. Opin. Immunol. 2005, 17, 411-418.
7. Frazer, I. H., Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev. Immunol. 2004, 4, 46-54.
8. Talon, J., Salvatore, M., O'Neill, R. E., Nakaya, Y. et al. Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc. Natl. Acad. Sci. USA. 2000, 97, 4309-4314.